11/12
04:30 pm
pbm
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
High
Report
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
10/31
09:33 am
pbm
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs [Financial Post (Toronto, Ontario, Canada)]
High
Report
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs [Financial Post (Toronto, Ontario, Canada)]
10/31
09:30 am
pbm
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
High
Report
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
10/31
07:30 am
pbm
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
Medium
Report
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
10/25
09:52 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care [Financial Post (Toronto, Ontari
Low
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care [Financial Post (Toronto, Ontari
10/25
09:50 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care [Yahoo! Finance]
Low
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care [Yahoo! Finance]
10/25
09:42 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Low
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
10/24
07:00 am
pbm
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
High
Report
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
10/17
07:00 am
pbm
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
High
Report
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
10/14
10:48 am
pbm
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical [Yahoo! Finance]
Low
Report
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical [Yahoo! Finance]
10/14
10:46 am
pbm
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical [Financial Post (Toronto, Ontario, Canada)]
10/14
10:43 am
pbm
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
Low
Report
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
10/4
04:21 pm
pbm
Psyence Biomedical to not proceed with Clairvoyant acquisition [Seeking Alpha]
Low
Report
Psyence Biomedical to not proceed with Clairvoyant acquisition [Seeking Alpha]
10/4
04:05 pm
pbm
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
Medium
Report
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
10/2
04:29 pm
pbm
Psyence Biomedical files to sell 10.9M common shares for holders. [Seeking Alpha]
High
Report
Psyence Biomedical files to sell 10.9M common shares for holders. [Seeking Alpha]
9/20
11:29 am
pbm
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs [Financial Post (Toronto, Ontario, Canada)]
9/20
11:28 am
pbm
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs [Yahoo! Finance]
Medium
Report
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs [Yahoo! Finance]
9/20
11:20 am
pbm
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
Medium
Report
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
9/19
07:30 am
pbm
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
High
Report
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
9/18
09:36 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones [Financial Post (Toronto, Ontario, Canada)]
9/18
09:30 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Medium
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
9/16
09:48 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care [Yahoo! Finance]
Medium
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care [Yahoo! Finance]
9/16
09:38 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care [Financial Post (T
Medium
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care [Financial Post (T
9/16
09:31 am
pbm
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
High
Report
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
9/16
07:30 am
pbm
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Medium
Report
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones